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Abstract
Background: Both hereditary and sporadic forms of chronic pancreatitis are associated with an
increased risk of developing pancreatic ductal adenocarcinoma (PDA). Inflammation has been identified
as a significant factor in the development of solid tumour malignancies. We have recently shown that
thymoquinone (Tq), the major constituent of Nigella sativa oil extract, induced apoptosis and inhibited
proliferation in PDA cells. Tq also increased p21 WAF1 expression, inhibited histone deacetylase (HDAC)
activity, and induced histone hyperacetylation. HDAC inhibitors have been shown to ameliorate
inflammation-associated cancer. In this study, we evaluated the anti-inflammatory potential of Tq in PDA
cells in comparison with that of a specific HDAC inhibitor, trichostatin A (TSA).
Methods: PDA cells were treated with or without Tq (25–75 mM), with or without pre-treatment of tumour
necrosis factor (TNF)-a (25 ng/ml). The effect of Tq on the expression of different proinflammatory
cytokines and chemokines was analysed by real-time polymerase chain reaction (PCR). Luciferase-
labelled promoter studies evaluated the effect of Tq on the transcription of monocyte chemoattractant
protein-1 (MCP-1) and nuclear factor-kB (NF-kB). The effect of Tq on the constitutive and TNF-a-induced
activation and nuclear translocation of NF-kB was examined by ELISA and immunohistochemistry.
Results: Tq dose- and time-dependently significantly reduced PDA cell synthesis of MCP-1, TNF-a,
interleukin (IL)-1b and Cox-2. At 24 h, Tq almost completely abolished the expression of these cytokines,
whereas TSA had a less dramatic effect. Tq, but not TSA, significantly and dose-dependently reduced the
intrinsic activity of the MCP-1 promoter. Tq also inhibited the constitutive and TNF-a-mediated activation
of NF-kB in PDA cells and reduced the transport of NF-kB from the cytosol to the nucleus.
Conclusions: Our data demonstrate previously undescribed anti-inflammatory activities of Tq in PDA
cells, which are paralleled by inhibition of NF-kB. Tq as a novel inhibitor of proinflammatory pathways
provides a promising strategy that combines anti-inflammatory and proapoptotic modes of action.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal
cancers of the gastrointestinal tract, with a death to incidence ratio
of 0.99.1 The poor prognosis of PDA is attributable to its tendency
for late presentation, aggressive local invasion, early metastasis
and resistance to chemotherapy.2 The only curative treatment is
surgical resection; however, only 10–15% of patients will have
localized disease at presentation.3 Retrospective studies show a
rising incidence of pancreatic tumours and mortalities.4–7 This, in
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addition to its poor prognosis, stresses the need to elucidate the
mechanisms underlying pancreatic carcinogenesis and to find
new treatments.
Several studies have observed an increased incidence of PDA in
patients with chronic pancreatitis,8–11 and all inflammatory cytok-
ines in chronic pancreatitis have been linked to pancreatic car-
cinogenesis. Familial chronic pancreatitis, which accounts for
<1% of all cases of pancreatitis, is also associated with increased
risk of PDA,12,13 especially with longer duration of the disease
process.14 In human PDA and in animal models that recapitulate
the disease progression, an intense fibro-inflammatory reaction
composed of stromal and immune cells accompanies the progres-
sion from normal histology to PDA.15–17
Studies on mouse models of inflammation-associated cancer
have implicated the transcriptional factor nuclear factor-kB (NF-
kB) and the proinflammatory mediator tumour necrosis factor-a
(TNF-a) in cancer progression.18,19 The NF-kB pathway may have
dual actions in tumour promotion, firstly, by preventing the death
of cells with malignant potential, and, secondly, by stimulating the
production of proinflammatory cytokines in inflammatory cells
in the tumour mass.18 Constitutive activation of NF-kB has been
observed in a number of different PDA cell lines,20,21 but not in
non-tumorigenic pancreatic epithelial cells.22 Activation of NF-kB
has also been observed in animal models of pancreatic cancer21
and in human pancreatic tissue.22 NF-kB activation may also con-
tribute to the characteristic resistance of pancreatic tumour cells
to the apoptotic effect of chemotherapeutic agents.23,24 Thus,
inhibiting the activation of NF-kB could be a useful adjunct in the
medical management of the disease.
Herbal therapies are commonly used for the prevention and
treatment of cancer, although we have little understanding of their
molecular and cellular bases of action. Nigella sativa, or the black
cumin seed, is a herb used in traditional medicine in many Middle
Eastern and Asian countries to treat a broad array of diseases.
Thymoquinone (Tq) (2-isopropyl-5-methyl-1,4-benzoquinone),
the most abundant constituent of the seed oil extract, has been
shown to have anti-neoplastic activities in different types of
cancer.25–28 Tq also has cytoprotective effects that are mainly medi-
ated through its antioxidant and anti-inflammatory activities.29
Despite Tq’s interesting potential as an anti-neoplastic agent, its
anti-inflammatory effects in PDA cells have not been evaluated.
We have recently shown that Tq reduces PDA cell growth and
promotes apoptosis through increasing the Bax-Bcl-2 ratio, acti-
vating capase-3, and inhibiting histone deacetylase (HDAC)
activity and transcription.30 In this study, we evaluated the anti-
inflammatory potential of Tq in PDA cells in comparison with a
specific HDAC inhibitor, trichostatin A (TSA).
Materials and methods
Cell culture and treatments
HS766T PDA cells, kindly provided by Dr Scott Kern, Johns
Hopkins University School of Medicine, Baltimore, MD, USA,
were used for all the experiments. MiaPaca and AspC-1 cells,
which were purchased from the American Type Culture Collec-
tion (Manassas, VA, USA), were used in some experiments to
confirm the results. Cells were cultured at 1 ¥ 104 to near conflu-
ence in six-well plates and maintained in DMEM (Dulbecco’s
modified Eagle’s medium) supplemented with 10% fetal bovine
serum in a humid atmosphere of 5% CO2 : 95% air. A purified
preparation of Tq (Fisher) was dissolved in methanol and serial
concentrations were prepared. Controls were treated with vehicle
only. For all experiments, cell lines were treated with or without
Tq (25–75 mM) or the HDAC inhibitor, TSA (300 mM). In some
experiments, TNF-a (25 ng/ml) was added 30 min before adding
Tq or TSA, to elicit inflammation. Tq and TSA were obtained
from Sigma-Aldrich, Inc. (St Louis, MO, USA) and TNF-a was
purchased from R&D Systems, Inc. (Minneapolis, MN, USA).
RNA extraction and real-time reverse transcription
polymerase chain reaction
Total RNA was isolated using Trizol reagent (Life Technologies,
Inc., Gaithersburg, MD, USA). RNAs were quantified and input
amounts were optimized for each amplicon. Primers and probes
were designed with the help of Primer Express software (Applied
Biosystems, Inc., Foster City, CA, USA). Primers and probes were
selected for the following cytokines and chemokines: TNF-a;
interleukin-b (IL-1b); cyclooxiygenase-2 (Cox-2); IL-8, and
monocyte chemoattractant protein-1 (MCP-1). GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was used as the
housekeeping gene. cDNA was prepared, diluted and subjected to
real-time polymerase chain reaction (PCR) using TaqMan tech-
nology (7500 Sequence Detector; Applied Biosystems, Inc.).
Probes were labelled with a reporter and a quencher. Each
sample was analysed in at least two independent assays with
duplicate samples and the corresponding no-reverse transcrip-
tase (RT) mRNA sample was included as a negative control.
The relative mRNA levels were presented as unit values of 2∧
[CT (GAPDH)–CT (gene of interest)], where CT is the threshold cycle value
defined as the fractional cycle number at which the target fluores-
cent signal passes a fixed threshold above baseline.
Transient transfection and promoter studies
To evaluate the effect of Tq on MCP-1 and NF-kB transcription,
we used the MCP-1 gene promoter (GenBank™ accession no.
AF079313) and NF-kB gene promoter (GenBank™ accession no.
in progress) in luciferase expression vector pGL3 basic (Promega,
Madison, WI, USA), kindly provided by Dr Decio Ezirik, Free
University of Brussels, Brussels, Belgium.31 HS766T cells were
seeded into 24-well culture plates (105). At ~80% confluence they
were co-transfected by TransFast reagent (Promega) and 0.5 mg of
pGL3 vectors containing the luciferase-labelled MCP-1 or NF-kB
promoters and 0.1 mg of green fluorescence protein (GFP) as
transfection control. Two hours later, serum-containing medium
was overlaid and the cells were incubated for an additional
24 h. The cells were then incubated with serum-free medium for
18 h, after which Tq (25–75 mM) was added for 3 h. In some
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experiments, cells were pre-treated with TNF-a (25 ng/ml) for
30 min before adding Tq or TSA. Luciferase activities were assayed
with the Dual-Luciferase Reporter Assay System (Promega Corp.)
in a Veritas Microplate Luminometer (Turner Designs, Sunnyvale,
CA, USA). Transfection efficiency was normalized using the total
protein concentration of the cell lysates. The results for Tq-treated
cells were expressed as a fold-induction of the luciferase activity of
the same construct in control condition, taking a control (no
treatment) value as 1.
NF-kB activation assay
NF-kB activation was analysed using quantification of nuclear
translocation with the NF-kB/p65 ActivELISA kit to detect the
active form of the p65 subunit (Imgenex Corp, San Diego, CA,
USA). Briefly, whole-cell extracts were prepared from 5 ¥ 105
HS766T cells that were subjected to TNF-a (25 ng/ml) for 30 min,
followed by a 1-h incubation with Tq (75 mM) or TSA (300 mM).
Cytoplasmic and nuclear extracts were prepared according to the
manufacturer’s instructions. Briefly, the cytoplasmic fraction was
collected in the supernatant of the whole-cell lysates after cen-
trifugation for 30 s at 28 487 g in a cold microcentrifuge. Nuclear
fraction was collected in the supernatant of the nuclear pellet after
its resuspension in 100 ml nuclear lysis buffer, incubation at 4 °C
for 30 min, and centrifugation in a microcentrifuge at 28 487 g for
10 min at 4 °C. Nuclear fractions were subjected to ELISA
(enzyme-linked immunosorbent assay) using specific, anti-
NF-kB antibodies, according to the manufacturer’s instructions.
Absorbance was read at a 405-nm wavelength using a Synergy HT
multi-detection microplate reader (Bio-Tek Instruments, Inc.,
Winooski, VT, USA).
Immunohistochemical staining of PDA cells
HS766T cells were grown in chamber slides (lab-tech, NUNC;
Thermo Fisher Scientific, Inc., Rochester, NY, USA). To study the
localization of the p65 NF-kB subunit, cells were treated with
TNF-a (25 ng/ml) for 30 min before adding Tq (75 mM) or TSA
(300 mM) for 1 h, after which they were washed with Hanks bal-
anced salt solution, pH 7.4, at 37 °C after aspiration of the culture
medium. Cells were then fixed in 4% formaldehyde in phosphate
buffered saline (PBS) at room temperature for 10 min before
being treated with 0.1% Triton X-100 for 30 s to permeabilize
nuclear membranes. After blocking non-specific reaction with
normal donkey serum, the cells were incubated overnight with
anti-rabbit p65 IgG (400 ng/ml) at 4 °C. Cells were then washed
three times for 5 min each with PBS and incubated for 30 min at
room temperature with biotinylated goat anti-rabbit IgG, diluted
1 : 200 in PBS (Vector Laboratories, Inc., Burlingame, CA, USA),
as the secondary antibody. 3,3′-diaminobenzidine tetrahydro-
chloride chromogenic substrate (Vector Laboratories, Inc.) was
used according to the manufacturer’s protocol to visualize the
chromogenic reaction. Cells were rinsed three times for 5 min
each with PBS, counterstained with haematoxylin, mounted on
glass slides and viewed by light microscopy.
Statistical analysis
All experiments were performed between four and six times. Data
were analysed for statistical significance by anova with post-hoc
Student’s t-test analysis. Data are presented as mean  standard
error of the mean (SEM). Continuous normally distributed vari-
ables were analysed by Student’s t-test. These analyses were per-
formed with the assistance of a computer program (jmp 5; SAS
Software Corp., Cary, NC, USA). Differences were considered sig-
nificant at P  0.05.
Results
Tq dose-dependently reduces the expression of
TNF-a and MCP-1
Real-time reverse transcriptase (RT)-PCR was used to analyse the
effect of different doses of Tq (25–75 mM) on expression levels of
TNF-a and MCP-1 mRNA in HS766T cells. Cells were treated
with Tq for 6 h. As Fig. 1A shows, Tq significantly reduced the
expression in both genes (P < 0.05 at 50 mM and P < 0.02 at
75 mM, respectively).
Tq significantly reduces the expression of different
proinflammatory cytokines and chemokines in
HS766T cells
Next, we analysed the effect of Tq on the expression levels of
proinflammatory cytokines and chemokines in HS766T cells and
compared these with the effects of TSA at different time-points.
Cells were treated with Tq (75 mM) and TSA (300 mM) for 3 h, 6 h
and 24 h. With the exception of IL-8, levels of which seem to
initially increase after 3 h of Tq treatment, the remaining cytok-
ines showed significant reductions (MCP-1 and TNF-a [P < 0.05];
Cox-2 [P < 0.02]). After 24 h, Tq almost completely abolished
the transcription of all examined cytokines and chemokines
(Fig. 1A). TSA was variably effective in reducing the expression of
the cytokines. At 24 h, however, it significantly reduced expression
of MCP-1 (P < 0.005), TNF-a and Cox-2 (P < 0.002), but had less
significant effects on IL-8 and IL-1b (P < 0.05).
Tq reduces the expression of TNF-a in AsPC-1 and
MiaPaca cells
To test the sensitivity of other PDA cells to Tq, we evaluated its
effect on the expression of TNF-a in AsPC-1 and MiaPaca cells.
Cells were treated with Tq (75 mM) and TSA (300 mM) for 3 h,
6 h, 12 h and 24 h. Figure 1C shows that both cell lines were sen-
sitive to Tq and TSA at 3–6 h, when TNF-a mRNA was undetect-
able. Interestingly, at 12 h, TNF-a mRNA levels started to
increase, especially in the Tq-treated cells. TNF-a expression was
increased at 24 h with Tq and TSA treatment, suggesting that PDA
cells may vary in their sensitivity to Tq and that a different treat-
ment regimen should be adopted with each cell line to assure the
consistent reduction of TNF-a levels.
Tq dose-dependently and significantly reduces the
endogenous activity of MCP-1 promoter
MCP-1, a protein from the C-C chemokine subfamily, is
expressed in human PDA and in some PDA cell lines.32 The
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potential contribution of MCP-1 to PDA progression is of major
interest because MCP-1 production correlated with the levels of
macrophage content in transplanted tumours in vivo.33,34 To
evaluate the effect of Tq on MCP-1 transcription, HS766T cells
were transfected with luciferase-labelled MCP-1 promoters and
treated with Tq (25, 50, 75 mM) and TSA (50, 150, 300 mM) for
3 h. As seen in Fig. 2, Tq dose-dependently reduced the
luciferase activity of the MCP-1 promoter. TSA did not have a
significant effect on the endogenous activity of the MCP-1 pro-
moter (Fig. 2).
Figure 1 (A) Tq dose-dependently
reduces the expression of TNF-a and
MCP-1. Real-time polymerase chain
reaction (PCR) of HS766T cells after
incubation with Tq (25–75 mM) for 6 h. Tq
dose-dependently reduces the expres-
sion of TNF-a and MCP-1. Data are
expressed as mean  standard error of
the mean. Each experiment was per-
formed three times and repeated three
times for reproducibility. *P < 0.05, †P <
0.02 vs. untreated control cells using
one-way repeated ANOVA with subse-
quent all pairwise comparison procedure
by Student's t-test. (B) Tq time-
dependently reduces the expression of
different proinflammatory cytokines and
chemokines. HS766T cells were incu-
bated with Tq (75 mM) or TSA (300 mM)
for 3 h, 6 h and 24 h. At 24 h, Tq almost
completely abolished the expression of
MCP-1, TNF-a, Cox-2, IL-8 and IL-1b,
whereas TSA had a less significant
effect. *P < 0.05, †P < 0.005, ‡P < 0.002
vs. untreated control cells using one-way
repeated ANOVA with subsequent all pair-
wise comparison by Student's t-test. (C)
Tq reduces the expression of TNF-a in
AsPC-1 and MiaPaca cells. Cells were
subjected to real-time PCR after treat-
ment with Tq (75 mM) or TSA (300 mM)
for 3 h, 6 h, 12 h and 24 h. *P < 0.05 vs.
untreated control cells using one-way
repeated ANOVA with subsequent all pair-
wise comparison by Student's t-test
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Tq time-dependently reduces the constitutive and
TNF-a-induced activation of NF-kB in HS766T and
MiaPaca cells
Activation of the transcription factor NF-kB is an essential step
for activating the transcription of different cytokines and
chemokines examined. We investigated whether Tq mediates its
cytokine/chemokine-regulatory effect through inhibition of the
constitutive and/or TNF-a-induced NF-kB activation. We evalu-
ated p65 nuclear translocation in HS766T cells after their treat-
ment with or without TNF-a by two independent assays: p65
NF-kB activity assay, and nuclear immunolocalization. HS766T
cells were treated with Tq (75 mM) and TSA (300 mM) for 30 min,
1 h and 2 h (Fig. 3A). To analyse the effect of Tq on the TNF-a-
mediated activation of NF-kB, cells were pre-treated with TNF-a
(25 ng/ml) for 30 min, and then treated with Tq (75 mM) or TSA
(300 mM) for 1 h. Cells were analysed for the presence of active
forms of NF-kB p65 using the ActivELISA kit (Imgenex Corp.).
The anti-p65 antibody-coated plate captures free p65 and the
amount of active p65 is detected by colorimetric detection at OD
405 after adding a second anti-p65 antibody followed by alkaline
phosphatase-conjugated secondary antibody. As early as after
30 min, Tq alone reduced the constitutive activity of NF-kB in
HS766T cells by ~1.7-fold, compared with a 1.5-fold reduction by
TSA (Fig. 3A) (P < 0.05). TNF-a increased the activation of
NF-kB 1.54-fold, an effect that was reduced 2.72-fold by Tq
(75 mM) (P < 0.005). TSA had similar effects (Fig. 3A).
In MiaPaca cells, Tq alone reduced the constitutive activity of
NF-kB by ~1.8-fold, compared with 1.6-fold by TSA (Fig. 3B).
TNF-a increased the activation of NF-kB 1.78-fold, an effect that
was reduced more than three-fold by Tq (75 mM) (P < 0.002). TSA
had a lesser but still significant effect whereby it reduced the
activation of NF-kB 2.3-fold (Fig. 3B) (P < 0.005). These findings
suggest that one mechanism by which Tq reduces inflammation is
the inhibition of the constitutive and TNF-a-mediated activation
of NF-kB.
Tq reduces the TNF-a-mediated nuclear translocation
of NF-kB
Immunohistochemical staining with anti-rabbit p65 IgG was used
to analyse the nuclear translocation of NF-kB after pre-treatment
with TNF-a and subsequent treatment with Tq or TSA. The
number of clearly stained nuclei in 10 fields was averaged, and the
data were calculated as the percentage of nuclear staining/total
number of nuclei. In the control untreated cells, a diffuse cyto-
plasmic staining was observed, whereas cells treated with TNF-a
had a clear nuclear staining, indicating nuclear translocation of
p65. Adding Tq to the cells prevented the TNF-a-induced nuclear
translocation of p65 in HS766T cells more significantly than did
TSA (P < 0.02 and P < 0.05, respectively) (Fig. 4A) (control 8 
0.8 stained nuclei/105 nuclei; TNF-a 94  21 stained nuclei/105
nuclei; TNF-a + Tq 12  0.4 stained nuclei/105 nuclei; TNF-a +
TSA 34  15 stained nuclei/105).
Tq dose-dependently reduces the constitutive and
TNF-a-induced activation of NF-kB promoter
To further elucidate the effect of Tq on NF-kB, we investigated
whether Tq has a direct effect on NF-kB transcription. HS766T
cells were transfected with luciferase-labelled NF-kB promoter
and then treated with Tq (25–75 mM) or TSA (50–300 mM) for
3 h. As seen in Fig. 4B, there was a dose-dependent decrease in
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Figure 2 Tq dose-dependently reduces the intrinsic activity of MCP-1 promoter. HS766T cells were transfected with luciferase-labelled
MCP-1 promoter. Relative luciferase activity was calculated after deduction of the activity levels with pGL3 vector alone. Results represent
mean  standard error of the mean of triplicate determinations. All experiments were repeated at least three times to confirm reproducibility.
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endogenous NF-kB promoter activation as well as a significant
(P < 0.05) decrease in cells pre-treated with TNF-a after Tq
treatment. TSA had no effect on the endogenous or TNF-a-
induced activation of the NF-kB promoter. These data suggest
that Tq not only regulates the activity of NF-kB, but also regulates
its transcription.
Discussion
Herbs as alternative cancer therapies have attracted a great deal of
recent attention as a result of their low toxicity and costs. In this
study, we investigated the potential anti-inflammatory effects of
Tq, the major constituent of the Middle Eastern herbNigella sativa,
in PDA cells.We show that Tq has strong anti-inflammatory activi-
ties in several PDA cell lines. We demonstrate that Tq mediates its
effects through reducing the activity and transcription of NF-kB.
Evidence for the anti-neoplastic activities of Tq has been reported,
with various observations ranging from the activation of genes that
promote apoptosis to the activation of proapoptotic pathways in
several types of cancer.30,35 Until now, however, there have been no
reports analysing the anti-inflammatory potential of Tq in PDA
cells. Thus, the present study is the first to analyse the anti-
inflammatory effects of Tq in PDA cells.
TNF-a plays an essential role in many inflammatory condi-
tions. In accordance with its overwhelming importance in inflam-
matory processes, several lines of evidence point to a tumour-
promoting function of TNF-a. Studies have shown that
overexpression of TNF-a confers invasive properties in a cell type-
dependent manner in nude mice.36–38 A crucial role of TNF-a in
the initiation of skin tumours and hepatic carcinogenesis is
evident from studies of TNF-a and TNF receptor-1 knockout
mice.39–41 A variety of tumour-promoting effects of TNF-a have
been shown in vitro and include protection against physiologic
and pharmacologic apoptosis inducers, induction of angiogenic
factors, enhancement of tumour cell motility, activation of onco-
genic pathways, and triggering of epithelial to mesenchymal
transition.42 Our in vitro data show that Tq significantly reduced
mRNA expression of multiple proinflammatory cytokines and
chemokines, mainly TNF-a (Fig. 1A–C).
Several investigations have provided recent evidence for the
potential contribution of MCP-1 to cancer progression.32,34
MCP-1 produced by pancreatic tumour cells could promote the
recruitment of monocytes or macrophages. Immune cells or other
stromal cells within the tumour release inflammatory cytokines,
including TNF-a and IL-1b, which, in turn, increase MCP-1 pro-
Figure 3 Tq inhibits the constitutive and
TNF-a-mediated activation of NF-kB.
Lysates from (A) HS766T cells and (B)
MiaPaca cells treated with Tq (75 mM)
and TSA (300 mM) with or without pre-
treatment with TNF-a (25 ng/ml) were
analysed for the presence of the active
forms of NF-kB p65 using the
ActivELISA kit. Both Tq and TSA demon-
strated significant downregulation of the
constitutive and TNF-a-mediated NF-kB
p65 activation. Values are expressed
as mean  standard error of the mean
of three experiments. *P  0.05 vs.
untreated control values; †P < 0.02
vs. control untreated values; ‡P < 0.005
vs. TNF-a-treated values, using one-way
repeated ANOVA with subsequent all pair-
wise comparison by Student's t-test
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duction and amplify monocyte recruitment.42 Our data here
show that in HS766T cells, Tq potently reduced MCP-1 mRNA
expression levels, time- and dose-dependently (Fig. 1A–B). TSA
had variable and less significant effects. This may be explained by
the direct effect of Tq on MCP-1 promoter, where it reduced its
intrinsic activity (Fig. 2). Studies to elucidate the exact mecha-
nism through which Tq reduces the activity of MCP-1 promoter
are ongoing in our laboratory.
The NF-kB pathway is regularly and robustly activated by
TNF-a and mediates many of the pro-tumoral effects of TNF-a.
As treating cells with Tq inhibited the transcription of many
inflammatory cytokines, such as IL-1b, IL-8, and chemokines,
such as MCP-1, we studied the transcription factor NF-kB as a
possible target for Tq-mediated effects. NF-kB comprises a col-
lection of dimers composed of various combinations of members
of the Rel family. Five mammalian Rel proteins have been identi-
fied: p50, p52, c-Rel, p65 (RelA) and RelB. NF-kB is sequestered in
the cytoplasm by binding to inhibitor protein k Ba (IkBa). Fol-
lowing cytokine exposure, IkBa is phosphorylated, ubiquitinated
and degraded by the proteasomal complex exposing the NF-kB
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Figure 4 Tq reduces the TNF-a-mediated nuclear translocation of NF-kB. (A) Immunohistochemical staining for p65 NF-kB subunit shows
mainly cytoplasmic staining in the control cells (large green arrows). Control cells treated with TNF-a show intense nuclear staining (black
arrows), whereas Tq- and, to a lesser extent, TSA-treated cells show inhibition of the TNF-a-induced nuclear translocation in most of the
cells (green arrows), and few cells retain their nuclear staining (small black arrows). (B) Tq dose-dependently reduces the constitutive and
TNF-a-induced activation of NF-kB promoter. HS766T cells were transfected with luciferase-labelled NF-kB promoter. Relative luciferase
activity was calculated after deduction of the activity levels with pGL3 vector alone. Results represent mean  standard error of the mean
of triplicate determinations. All experiments were repeated at least three times to confirm reproducibility. (*P < 0.05, vs. untreated control
cells by Student's t-test)
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nuclear recognition site to translocate to the nucleus and bind kB
consensus sequences in promoter regions of numerous proin-
flammatory genes such as TNF-a.43 NF-kB activation has been
reported in PDA cell lines and primary tumour samples.44,45 Fur-
thermore, increased TNF-a levels were found in patients suffering
from pancreatic cancer.46 Our data demonstrate, for the first time,
that Tq inhibits the constitutive and TNF-a-induced activation of
NF-kB (Fig. 3A, B) and inhibits the translocation of NF-kB to the
nucleus in PDA cells (Fig. 4A). These data are consistent with
recent data published by Sethi et al.,47 which showed similar
effects of Tq in myeloid and embryonic kidney cells.
Most interestingly, Tq inhibited the transcription of NF-kB
through reducing its promoter activity (Fig. 4B), indicating that
Tq has a dual inhibitory effect, the first through inhibiting the
NF-kB signalling pathway and the second through inhibiting its
transcription. The details of the mechanism by which Tq down-
regulates NF-kB promoter activity are still unclear. Tq may induce
binding of transcription factors to the promoter or a suppressor
region. Alternatively, Tq may induce changes in the secondary and
tertiary structures of the promoter. Studies addressing transcrip-
tion factor binding are ongoing in our laboratory.
The potent anti-inflammatory effect of Tq on TNF-a and other
inflammatory mediators is promising for its potential as a preven-
tive and therapeutic strategy in PDA. Clinical trials with TNF-a-
blocking agents are currently underway in patients with solid
cancers. Thus far, these trials show that TNF-a blockers are well
tolerated, which is in good accordance with experience of anti-
TNF-a treatment in patients with chronic inflammatory dis-
eases.48 Therefore, the results presented in our study strongly
suggest that surgical resection of PDA combined with a Tq
therapy represents a promising novel therapeutic option. Corre-
sponding adjuvant clinical trials should therefore be pursued.
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